E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Inclusion Criteria: * Age \>= 18 years * Histologically or cytologically confirmed stage IV metastatic BRAF V600-mutated melanoma * Documented metastasis of the primary tumor to the CNS * BRAF-mutation melanoma tumor status will be established prior to entry based on previous BRAF-gene analysis reports from a Clinical Laboratory Improvement Act (CLIA) qualified laboratory. If a report is not available, the mutation analysis will be performed at screening on archival tissue * At least one brain metastasis, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) with contrast =\< 3 weeks prior to registration and does not require immediate local intervention (surgery or radiosurgery) * Asymptomatic or symptomatic CNS metastasis * Systemic, measurable metastatic melanoma disease is allowed; leptomeningeal disease is allowed. * Prior stereotactic radiosurgery and/or excision of brain metastases is allowed \> 3 weeks before initiation of study treatment * Prior immunotherapy for adjuvant or metastatic disease is allowed provided there is documented progression of disease following treatment * Prior melanoma adjuvant BRAF/MEK inhibitor treatment is allowed if \>= 12 months has elapsed between the end of therapy and initiation of study treatment * Able to swallow and retain oral medication with no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels * Stable do…